Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1

Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1

Autor Rodriguesa, MHC Google Scholar
Rodrigues, K. M. Google Scholar
Oliveira, T. R. Google Scholar
Comodo, A. N. Google Scholar
Rodrigues, M. M. Google Scholar
Kocken, CHM Google Scholar
Thomas, A. W. Google Scholar
Soares, I. S. Google Scholar
Instituição Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
Biomed Primate Res Ctr
Resumo In the present study, we evaluate the naturally acquired antibody response to the Plasmodium vivax apical membrane antigen 1 (PvAMA-1), a leading vaccine candidate against malaria. the gene encoding the PvAMA-1 ectodomain region (amino acids 43-487) was cloned by PCR using genomic DNA from a Brazilian individual with patent P. vivax infection. the predicted amino acid sequence displayed a high degree of identity (97.3%) with a previously published sequence from the P. viva-v Salvador strain. A recombinant protein representing the PvAMA-1 ectodomain was expressed in Escherichia coli and refolded. By ELISA, this recombinant protein reacted with 85 and 48.5% of the IgG or IgM antibodies, respectively, from Brazilian individuals with patent P. vivax malaria. IgG I was the predominant subclass of IgG. the frequency of response increased according to the number of malaria episodes, reaching 100% in individuals in their fourth malaria episode. the high degree of recognition of PvAMA-1 by human antibodies was confirmed using a second recombinant protein expressed in Pichia pastoris (PV66/AMA-1). the observation that recognition of the bacterial recombinant PvAMA-1 was only slightly lower than that of the highly immunogenic 19 kDa C-terminal domain of the P. vivax Merozoite Surface Protein-1 was also important. DNA sequencing of the PvAMA-1 variable domain from 20 Brazilian isolates confirmed the limited polymorphism of PvAMA-1 suggested by serological analysis. in conclusion, we provide evidence that PvAMA-1 is highly immunogenic during natural infection in humans and displays limited polymorphism in Brazil. Based on these observations, we conclude that PvAMA-1 merits further immunological studies as a vaccine candidate against P. vivax malaria. (C) 2004 Australian Society for Parasitology Inc. Published by Elsevier B.V. All rights reserved.
Assunto malaria
Plasmodium vivax
Idioma Inglês
Data 2005-02-01
Publicado em International Journal for Parasitology. Oxford: Pergamon-Elsevier B.V., v. 35, n. 2, p. 185-192, 2005.
ISSN 0020-7519 (Sherpa/Romeo, fator de impacto)
Editor Elsevier B.V.
Extensão 185-192
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000227323600008

Mostrar registro completo

Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)